Alzheimer's hidden trigger: amyloid beta displaces tau protein in nerve cells
A UC Riverside team proposes that amyloid beta and tau compete for the same binding sites on microtubules, so amyloid can displace tau and disrupt transport inside neurons.
- Researchers at the University of California, Riverside propose that amyloid beta and tau share the same binding sites on neuronal microtubules.
- The two proteins bind with roughly equal strength, so amyloid can displace tau if it builds up inside the cell.
- Once tau loses its place, the cell's internal transport network begins to break down and tau clumps together.
- The model suggests the buildup may be a consequence of deeper cellular problems rather than the original cause of the disease.
A team at the University of California, Riverside (UC Riverside) has put forward a new account of what happens inside nerve cells at the very onset of Alzheimer’s disease. In their model, the two proteins long linked to the disease, amyloid beta and tau, do not act independently. Instead they compete for the same binding sites on microtubules, the internal rails along which a neuron moves materials.
That is a shift in framing. For years amyloid plaques and tau tangles were treated as two separate phenomena that meet late in the course of the disease. The proposed mechanism ties them together at the level of a single cell and at the binding site where both proteins attach.
Microtubules are part of the nerve cell’s skeleton and the backbone of its transport system. Tau normally binds to them and helps keep them stable while cargo travels from the cell body to the ends of its long extensions. According to the researchers, amyloid beta binds to the same sites, and with roughly the same strength as tau.
How amyloid displaces tau
If amyloid beta accumulates inside a neuron, that similar affinity means it can push tau off its place on the microtubules. “Our work shows that amyloid beta and tau compete for the same binding sites on microtubules and that amyloid can prevent tau from functioning properly,” the authors note.
The consequences, in this model, ripple through the cell. When tau loses its place, the transport network starts to break down. The unbound tau clumps together and migrates into parts of the neuron where it does not normally belong, which matches what is seen in Alzheimer’s as tau tangles.
It is worth being clear about what this is and is not. It is a proposed mechanism grounded in how the proteins bind, not proof that this competition is the only or main cause of disease in people. The work describes a process at the molecular and cellular level; linking it to the clinical course in patients will require further testing.
What if plaques are not the first cause?
The model also raises a broader question. If amyloid only crowds out tau once it has built up inside the neuron, then the buildup of amyloid and tau itself could be a consequence of some deeper cellular failure rather than the original trigger. That differs from the view, around which many therapies have been built, that plaques are the first and primary cause.
For now this is a hypothesis to be tested in cell and animal models before anyone draws conclusions about treatment. No single paper rewrites the picture of a disease on its own, but it moves the question from “how much plaque is there” to “why does it form at all”.
Could shifting the focus from the plaques to their cause redirect future Alzheimer’s research?
